AZD1222, developed by the University of Oxford and licenced to AstraZeneca, was among the first vaccines created to protect against COVID-19. A non -replicating viral vector vaccine which was ...
These symptoms had started around 2 weeks after his second AZD1222 vaccination. Endocrinological tests revealed central diabetes insipidus and mild prolactinemia, but no basal or dynamic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback